Publications by authors named "Laslo Roman"
Objectives: Cisplatin and mitomycin C exert high activity towards BRCA1-deficient cells. This study aimed to evaluate the efficacy of a combination of these drugs in hereditary BRCA1-associated ovarian cancer (OC).
Methods: Twelve OC patients, who could not be treated by primary debulking surgery owing to extensive tumor spread, were given neoadjuvant cisplatin (100 mg/m) and mitomycin C (10 mg/m) every 4 weeks for 3 (n = 9), 2 (n = 2), or 4 (n = 1) cycles.
Background/aim: Russian Federation is among the high-incidence countries for gastric cancer (GC), with the incidence being projected to continue increasing. Using a non-invasive blood test with four stomach-specific biomarkers (pepsinogen-I (PG-I) and -II (PG-II), amidated gastrin-17 (G-17) and Helicobacter pylori (HP) IgG antibodies) in a hospital-based screening setting, we aimed to determine the prevalence of GC risk conditions: HP-infection and atrophic gastritis (AG).
Patients And Methods: A population-derived cohort of 918 asymptomatic subjects (646 women and 272 men) with a mean age of 51.
Purpose: We evaluated the influence of RAS mutation status on the treatment effect of panitumumab in a prospective-retrospective analysis of a randomized, multicenter phase III study of panitumumab plus fluorouracil, leucovorin, and irinotecan (FOLFIRI) versus FOLFIRI alone as second-line therapy in patients with metastatic colorectal cancer (mCRC; ClinicalTrials.gov, NCT0039183).
Experimental Design: Outcomes were from the study's primary analysis.
Purpose: This double-blind, phase III study aimed to demonstrate that sunitinib plus FOLFIRI (fluorouracil, leucovorin, and irinotecan) was superior to placebo plus FOLFIRI in previously untreated metastatic colorectal cancer (mCRC).
Patients And Methods: Patients were randomly assigned to receive FOLFIRI and either sunitinib (37.5 mg per day) or placebo (4 weeks on treatment, followed by 2 weeks off [schedule 4/2]) until disease progression.
Article Synopsis
- This study investigates the effectiveness of combining pertuzumab and trastuzumab with docetaxel, or using them without chemotherapy, for treating HER2-positive breast cancer in a neoadjuvant setting.
- In a phase 2 trial with 417 women, those who received the combination of pertuzumab, trastuzumab, and docetaxel achieved a higher rate of complete tumor response compared to those receiving just trastuzumab and docetaxel.
- Among the groups analyzed, the combination therapy (Group B) showed a pathological complete response rate of 45.8%, which was significantly better than the 29.0% seen in the group receiving only trastuzumab and docetaxel.
Article Synopsis
- Trastuzumab improves outcomes for patients with HER2-positive metastatic breast cancer, but many eventually see disease progression.
- Pertuzumab offers a complementary approach and has shown promise in combination with trastuzumab, leading to a study involving 808 patients to compare treatment effectiveness.
- Results revealed that the combination therapy significantly increased median progression-free survival (18.5 months vs 12.4 months) without a notable rise in severe side effects, suggesting it could be a better first-line treatment option.
Purpose: Panitumumab is a fully human anti-epidermal growth factor receptor (EGFR) monoclonal antibody that improves progression-free survival (PFS) in chemotherapy-refractory metastatic colorectal cancer (mCRC). This trial evaluated the efficacy and safety of panitumumab plus fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone after failure of initial treatment for mCRC by tumor KRAS status.
Patients And Methods: Patients with mCRC, one prior chemotherapy regimen for mCRC, Eastern Cooperative Oncology Group performance status 0 to 2, and available tumor tissue for biomarker testing were randomly assigned 1:1 to panitumumab 6.